NSETrading Window25 Jun 2026 · 25 Jun 2026, 02:59 pm

Trading Window

Glenmark Pharmaceuticals Limited · GLENMARK

✦ AI Summary

Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Analysis Scores

Earnings Impact5/10
Growth Catalyst5/10
Governance Concern5/10
Regulatory Risk5/10
Balance Sheet Risk5/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

GLENMARK_25062026145851_BSE_NSE_TWC_signed.pdf

pdf

Download →
View document text
June 25, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 NSE Symbol: GLENMARK BSE Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 24/26-27 Our Reference No. 24/26-27 Dear Sir/ Madam, Sub: Closure of Trading Window for dealing in securities of the Company in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended Pursuant to the above Regulations and Company’s Code of Conduct for Prevention of Insider Trading, we wish to inform you that the Trading Window for dealing in securities of Glenmark Pharmaceuticals Limited (the “Company”) shall be closed for the Designated Persons viz. Directors, Key Managerial Personnel, Identified Employees/ Persons of the Company including the Immediate Relatives of the Designated Persons of the Company and for the Connected Persons commencing from July 01, 2026 and the same shall remain closed till the declaration of Unaudited Financial Results (Standalone and Consolidated) of the Company for the First Quarter ended June 30, 2026 and forty-eight hours thereafter. The date of the Board Meeting of the Company for the declaration of Unaudited Financial Results of the Company for the First Quarter ended June 30, 2026, will be intimated in due course. This intimation is also being uploaded on the Company’s website at www.glenmarkpharma.com. This is for your information, and you are requested to bring this to the notice of your constituents and take the above information on your record. Thanking You. For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com